Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600
Debt
Debt-to-Equity RatioN/A
Current Ratio10.68
Quick Ratio10.68
Price-To-Earnings
Trailing P/E Ratio-0.62
Forward P/E Ratio-3.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.98 million
Price / Sales99.94
Cash FlowN/A
Price / CashN/A
Book Value$5.91 per share
Price / Book1.84
Profitability
EPS (Most Recent Fiscal Year)($17.82)
Net Income$-38,740,000.00
Net Margins-1,479.91%
Return on Equity-132.11%
Return on Assets-68.11%
Miscellaneous
Employees35
Outstanding Shares18,170,000
Market Cap$186.23 million
Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions
What is Spero Therapeutics' stock symbol?
Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."
How were Spero Therapeutics' earnings last quarter?
Spero Therapeutics Inc (NASDAQ:SPRO) released its earnings results on Thursday, August, 9th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.08. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.62 million. Spero Therapeutics had a negative return on equity of 132.11% and a negative net margin of 1,479.91%. View Spero Therapeutics' Earnings History.
When is Spero Therapeutics' next earnings date?
What price target have analysts set for SPRO?
6 equities research analysts have issued 12 month price objectives for Spero Therapeutics' stock. Their predictions range from $26.00 to $30.00. On average, they anticipate Spero Therapeutics' stock price to reach $27.75 in the next twelve months. This suggests a possible upside of 154.8% from the stock's current price. View Analyst Price Targets for Spero Therapeutics.
What is the consensus analysts' recommendation for Spero Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spero Therapeutics.
What are Wall Street analysts saying about Spero Therapeutics stock?
Here are some recent quotes from research analysts about Spero Therapeutics stock:
- 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (8/16/2018)
- 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts throughout 2018+." (8/9/2018)
Who are some of Spero Therapeutics' key competitors?
Some companies that are related to Spero Therapeutics include NuCana (NCNA), Epizyme (EPZM), AMAG Pharmaceuticals (AMAG), Flexion Therapeutics (FLXN), Urogen Pharma (URGN), Insys Therapeutics (INSY), Dova Pharmaceuticals (DOVA), CymaBay Therapeutics (CBAY), Obseva (OBSV), Kura Oncology (KURA), Vectura Group (VEGPF), Verastem (VSTM), Basilea Pharmaceutica (BPMUF), ChemoCentryx (CCXI) and ANI Pharmaceuticals (ANIP).
Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the folowing people:
- Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 37)
- Mr. Joel D. Sendek, CFO & Treasurer (Age 51)
- Ms. Cristina Larkin, Chief Operating Officer (Age 48)
- Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 64)
- Ms. Sharon Klahre, Director of Investor Relations
When did Spero Therapeutics IPO?
(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
Who are Spero Therapeutics' major shareholders?
Spero Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include VHCP Management II LLC (3.30%), Aquilo Capital Management LLC (2.29%), BlackRock Inc. (2.38%), Granahan Investment Management Inc. MA (0.83%), Bank of New York Mellon Corp (0.14%) and Bank of New York Mellon Corp (0.17%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Institutional Ownership Trends for Spero Therapeutics.
Which institutional investors are selling Spero Therapeutics stock?
SPRO stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC. Company insiders that have sold Spero Therapeutics company stock in the last year include Ankit Mahadevia, Cristina Larkin and Joel Sendek. View Insider Buying and Selling for Spero Therapeutics.
Which institutional investors are buying Spero Therapeutics stock?
SPRO stock was bought by a variety of institutional investors in the last quarter, including Aquilo Capital Management LLC, Granahan Investment Management Inc. MA, BlackRock Inc., Bank of New York Mellon Corp, Bank of New York Mellon Corp and PNC Financial Services Group Inc.. Company insiders that have bought Spero Therapeutics stock in the last two years include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Insider Buying and Selling for Spero Therapeutics.
How do I buy shares of Spero Therapeutics?
Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spero Therapeutics' stock price today?
One share of SPRO stock can currently be purchased for approximately $10.89.
How big of a company is Spero Therapeutics?
Spero Therapeutics has a market capitalization of $186.23 million and generates $1.98 million in revenue each year. The company earns $-38,740,000.00 in net income (profit) each year or ($17.82) on an earnings per share basis. Spero Therapeutics employs 35 workers across the globe.
What is Spero Therapeutics' official website?
How can I contact Spero Therapeutics?
Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]
MarketBeat Community Rating for Spero Therapeutics (NASDAQ SPRO)
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
